TuisNBY • NYSEAMERICAN
add
NovaBay Pharmaceuticals Inc
Vorige sluiting
$0,70
Dagwisseling
$0,67 - $0,73
Jaarwisseling
$0,36 - $9,08
Markkapitalisasie
3,49 m USD
Gemiddelde volume
337,69 k
P/V-verhouding
-
Dividend-opbrengs
-
In die nuus
Finansieel
Inkomstestaat
Inkomste
Netto inkomste
| (USD) | Sep. 2024info | J/J-verandering |
|---|---|---|
Inkomste | 2,44 m | -1,61% |
Bedryfskoste | 2,65 m | 12,46% |
Netto inkomste | -1,21 m | 31,02% |
Netto winsgrens | -49,65 | 29,89% |
Wins per aandeel | -0,59 | 95,41% |
EBITDA | -1,05 m | -53,58% |
Effektiewe belastingkoers | — | — |
Balansstaat
Totale bates
Totale aanspreeklikheid
| (USD) | Sep. 2024info | J/J-verandering |
|---|---|---|
Kontant en korttermynbeleggings | 776,00 k | -77,65% |
Totale bates | 3,88 m | -69,83% |
Totale aanspreeklikheid | 2,80 m | -51,76% |
Totale ekwiteit | 1,07 m | — |
Uitstaande aandele | 4,89 m | — |
Prys om te bespreek | 3,17 | — |
Opbrengs op bates | -68,00% | — |
Opbrengs op kapitaal | -142,34% | — |
Kontantvloei
Netto kontantverandering
| (USD) | Sep. 2024info | J/J-verandering |
|---|---|---|
Netto inkomste | -1,21 m | 31,02% |
Kontant van bedrywe | -2,06 m | -466,21% |
Kontant van beleggings | -2,00 k | -100,00% |
Kontant van finansiering | 2,09 m | 462,05% |
Netto kontantverandering | 26,00 k | 102,13% |
Beskikbare kontantvloei | -1,48 m | -433,66% |
Meer oor
NovaBay Pharmaceuticals, Inc. is an Emeryville, California based clinical-stage biopharmaceutical company, focused on developing novel, fast-acting, synthetic anti-infectives compounds. These compounds are designed to mimic the body's defense system against infection. The company is currently focused on products for the eye care market. Major products include Avenova, cleared by FDA for lid and lash cleansing as part of a regimen for Blepharitis.
and NeutroPhase, used in treatment of Necrotizing Fasciitis Wikipedia
Gestig
2000
Webwerf
Werknemers
25
